Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

Item
http://www.wikidata.org/entity/Q44004828
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.Receptor imaging in the diagnosis and treatment of pituitary tumors.Pituitary tumors. Current concepts in diagnosis and managementGonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro.Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.Human pituitary adenomas. Recent advances in morphological studies.Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.The silent corticotropinoma: is clinical diagnosis possible?Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas.Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.Impaired estrogen-induced negative feedback on gonadotropin secretion in patients with gonadotropin-secreting and nonfunctioning pituitary adenomas.Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.
P2860

Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

Item
http://www.wikidata.org/entity/Q44004828
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@en
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@nl
type
label
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@en
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@nl
prefLabel
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@en
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Gonadotropin release by clinic ...... ng hormone, and bromocriptine.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698